[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-cancer":745},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,120,0,25,[9,58,98,136,196,221,246,284,311,360,383,405,431,453,479,499,523,546,568,587,610,631,670,700,721],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100597545",false,"NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":19,"type":20},104,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Breast Cancer","Cervical Cancer","Colon Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastric Cancer","Kidney Cancer","Liver Cancer","Lung Cancer","Head and Neck Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Rectal Cancer","Sarcoma","RECRUITING","2026-07-01",{"date":48,"type":49},"2026-07-02","ACTUAL",{"date":51,"type":49},"2026-02-11",{"date":53,"type":20},"2027-08-31",{"name":55,"class":56},"Alliance for Clinical Trials in Oncology","OTHER",18,{"id":59,"slug":4,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100602476","NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","130 Years",{"count":67,"type":20},100,"OBSERVATIONAL","This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[71,27,72,30,32,33,34,73,39,37,74,75,76,77,40,41,42,78,79,44,80,81,82,83,84,85,86],"Adenocarcinoma (NOS)","Bladder Cancer","Gastrointestinal Stromal Tumour","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Small Cell Lung Cancer","Testicular Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","2026-06-26",{"date":89,"type":49},"2026-06-29",{"date":91,"type":49},"2025-09-18",{"date":93,"type":20},"2028-03-30",{"name":95,"class":96},"AstraZeneca","INDUSTRY",17,{"id":99,"slug":4,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":107,"conditions":108,"keywords":119,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100618120","NCT07327489","Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)","Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies","ELEPHAS-05","Inclusion Criteria:\n\n1. Able and willing to provide informed consent for participation\n2. Age ≥18 years at time of consent.\n3. Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy.\n4. Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.\n\nExclusion Criteria:\n\n1. Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment.\n2. Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients.\n3. Pregnant person(s).",{"count":106,"type":20},2000,"This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.",[109,110,111,72,112,113,114,115,32,39,36,37,116,117,118],"Cancer","Immunotherapy","Advanced Solid Tumors Cancer","TNBC, Triple Negative Breast Cancer","Colorectal Cancer","DMMR Colorectal Cancer","MSI-H Colorectal Cancer","NSCLC (Non-small-cell Lung Cancer)","Skin Cancer","Melanoma (Skin Cancer)",[110,120,121,109,122,123,124,125,126,127],"Live Tumor Biopsy","Elephas","Imaging","Tumor Cutting","Treatment Response","Core Needle Biopsy","Forceps Biopsy","Punch Biopsy","2026-06-25",{"date":89,"type":49},{"date":131,"type":49},"2025-04-14",{"date":133,"type":20},"2038-04",{"name":121,"class":96},8,{"id":137,"slug":4,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":16,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":147,"studyType":68,"phases":4,"briefSummary":148,"conditions":149,"keywords":178,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"19 Years","110 Years",{"count":146,"type":20},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[41,83,38,33,150,31,43,151,27,152,153,154,35,37,155,156,157,158,72,36,159,42,81,160,84,161,162,163,164,165,166,167,168,79,117,169,170,171,29,172,74,44,173,174,40,32,85,175,176,177],"Thymus Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Penile Cancer","Ureter Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Leukemia","Unknown Primary Tumor","Multiple Myeloma","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[41,83,179,180,181,182,183,184,185,186,29,187,176,177],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor",{"date":89,"type":49},{"date":190,"type":49},"2013-11-01",{"date":192,"type":20},"2099-12",{"name":194,"class":56},"University of Nebraska",42,{"id":197,"slug":4,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":142,"sex":16,"minAge":202,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":21,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100644984","NCT07676383","Precision Navigation to Improve Community Cancer Screening Participation: A Dual-Cohort Cluster Randomized Trial","Effectiveness and Mechanisms of a Precision Navigation Intervention to Improve Community Cancer Screening Participation: A Dual-Cohort Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 45 to 74 years.\n2. Permanent resident of a participating community, defined as having lived in the community for at least 6 months during the past 12 months.\n3. Participating in the urban cancer screening program.\n4. Identified by the program risk assessment questionnaire as being at high risk for at least one of the following cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer.\n5. Has not yet completed the corresponding free clinical screening test for the high-risk cancer type or types.\n6. Able to complete electronic questionnaires and read intervention materials independently or with assistance. Paper materials and staff explanation will be provided for participants who do not use smartphones.\n7. Able and willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Previously diagnosed with any of the target cancers, including lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer.\n2. Severe cognitive impairment, severe mental illness, or other conditions that prevent the participant from receiving the intervention or completing study questionnaires.\n3. Planning to be away from the community for a long period during the next 6 months, defined as cumulative absence of more than 3 months.\n4. Currently participating in another interventional study that may affect cancer screening behavior.","45 Years","74 Years",{"count":205,"type":20},1500,[23],"This study will evaluate whether a precision navigation intervention can help community residents at high risk for cancer complete recommended cancer screening. The study will be conducted in communities participating in an urban cancer screening program in China.\n\nEligible participants will be adults aged 45 to 74 years who are permanent residents of participating communities and have been identified as being at high risk for at least one of five cancers: lung cancer, breast cancer, colorectal cancer, upper gastrointestinal cancer, or liver cancer. Participants must not have completed the corresponding free clinical screening before enrollment.\n\nThis is a dual-cohort, cluster randomized controlled trial. Communities, rather than individual participants, will be assigned to one of three groups: a precision navigation group, a usual health education group, or a waiting control group. Participants will be classified into two cohorts according to the number of cancers for which they are assessed as high risk. Cohort A will include participants at high risk for three or more cancers, and Cohort B will include participants at high risk for one or two cancers.\n\nParticipants in the precision navigation group will receive a personalized navigation report matched to their risk profile. The report will explain the screening tests most relevant to them, help them understand screening choices, and provide practical steps to support screening completion. Participants in the usual health education group will receive general cancer screening education materials. Participants in the waiting control group will not receive active screening promotion during the main intervention period, but will receive general education materials after the primary assessment.\n\nThe main outcome is whether participants complete the recommended cancer screening during follow-up. The study will also assess changes in screening-related decision conflict, anxiety, self-efficacy, and behavioral intention. A subgroup of participants will provide blood samples before and after the intervention to explore possible biological mechanisms related to stress, inflammation, and screening behavior.\n\nThe results may help improve community-based cancer screening programs and provide evidence for using personalized navigation strategies to increase screening participation among high-risk populations.",[209,38,29,113,210,37],"Cancer Screening","Upper Gastrointestinal Cancer","NOT_YET_RECRUITING","2026-06-24",{"date":214,"type":49},"2026-06-30",{"date":216,"type":20},"2026-06",{"date":218,"type":20},"2027-02",{"name":220,"class":56},"Hunan Cancer Hospital",{"id":222,"slug":4,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":147,"enrollmentInfo":227,"targetDuration":4,"studyType":21,"phases":229,"briefSummary":230,"conditions":231,"keywords":234,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":245},"100643118","NCT07642336","Erector Spinae Plane Block Versus Thoracic Epidural Analgesia for Open Liver Resection","Comparison of Postoperative Analgesic Efficacy Between Erector Spinae Plane Block and Thoracic Epidural Analgesia in Open Hepatectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* \\* Patients aged between 18 and 80 years old.\n\n  * American Society of Anesthesiologists (ASA) physical status classification I to III.\n  * Scheduled to undergo elective open liver resection (open hepatectomy).\n  * Patient provides written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Severe coagulation profile derangement prior to surgery (defined as International Normalized Ratio \\[INR\\] \\> 1.5 or 2.0, or Platelet count \\[PLT\\] \\\u003C 50 G\u002FL or 100 G\u002FL).\n\n  * Severe hepatic impairment (Child-Pugh Class C).\n  * Severe chronic obstructive pulmonary disease (COPD GOLD stage III-IV).\n  * Severe cardiac dysfunction with an ejection fraction (EF) \\\u003C 35%.\n  * Severe obesity with a Body Mass Index (BMI) \\> 40 kg\u002Fm².\n  * Localized infection at the planned puncture\u002Fneedle insertion site.\n  * Known allergy or hypersensitivity to local anesthetics (e.g., Ropivacaine) or opioids (e.g., Morphine).\n  * Pregnancy or current lactation.",{"count":228,"type":20},60,[23],"Background: Open liver resection is associated with severe postoperative pain. While thoracic epidural analgesia (TEA) is considered the gold standard for pain control, its clinical application is often limited by postoperative coagulation profile derangement, which increases the risk of epidural hematoma. Continuous erector spinae plane block (ESPB) has emerged as a promising, safer alternative with a lower risk of bleeding complications. Objective: This study aims to compare the postoperative analgesic efficacy, safety profiles, and impacts on respiratory function between ultrasound-guided continuous ESPB and TEA in patients undergoing elective open liver resection. Hypothesis: The investigators hypothesize that continuous ESPB using a programmed intermittent bolus (PIB) regimen is non-inferior to TEA regarding 72-hour postoperative pain scores at rest, while offering superior hemodynamic stability and fewer technique-related risks.",[232,233,37],"Liver Neoplasms","Hepatic Resection",[235,236,233],"Postoperative Pain","Acute Pain","2026-06-23",{"date":128,"type":49},{"date":240,"type":49},"2026-06-15",{"date":242,"type":20},"2026-08-20",{"name":244,"class":56},"Nguyen Toan Thang",1,{"id":247,"slug":4,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":21,"phases":255,"briefSummary":256,"conditions":257,"keywords":265,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":279,"leadSponsor":281,"locationsCount":283},"100641147","NCT07658313","Digitally Supported Prehabilitation Before Major Visceral Cancer Surgery","From Prehabilitation to Rehabilitation: A Feasibility Trial for Digitally Supported Prehabilitation in Major Visceral Oncologic Surgery","P2R-OncoVis","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Clinical diagnosis requiring major surgery of the pancreas, liver, bile ducts, stomach, or esophagus with curative intent\n* Confirmed indication for surgery by the multidisciplinary tumor board\n* Medical stability and physician clearance to participate in a prehabilitation exercise program\n* Willingness and ability to attend center-based prehabilitation exercise sessions three times per week, or once per week with additional tele-prehabilitation if travel time exceeds 40 minutes one way\n* Willingness and ability to perform home-based physical activities\n* Sufficient German language proficiency and digital literacy\n* Access to a smartphone or tablet device with internet connection\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Physical disability or mental impairment preventing safe participation in the study\n* Health care medical power of attorney not permitting independent consent\n* Non-elective, emergency, or revision surgery\n* Acute medical condition contraindicating participation in a structured prehabilitation program",{"count":254,"type":20},30,[23],"Major visceral oncologic surgery is associated with high postoperative morbidity, prolonged hospitalization, delayed recovery, and reduced quality of life. Patients undergoing surgery of the pancreas, liver, bile ducts, stomach, or esophagus frequently present with reduced physical fitness, malnutrition, sarcopenia, and psychological distress, all of which may negatively affect surgical outcomes and rehabilitation. Although prehabilitation has shown potential to improve functional capacity before surgery, structured prehabilitation pathways are currently not routinely implemented in Austria, and the feasibility of digitally supported perioperative care pathways remains insufficiently evaluated.\n\nThe aim of the Prehab2Rehab-OncoVis study is to evaluate the feasibility, acceptability, and safety of a multimodal, digitally supported prehabilitation intervention for patients undergoing major visceral oncologic surgery with curative intent. The study will additionally explore potential effects on clinical recovery, functional capacity, rehabilitation outcomes, and patient-reported outcomes across the perioperative pathway.\n\nPrehab2Rehab-OncoVis is designed as a prospective, single-arm feasibility cohort study conducted at the University Hospital Salzburg and the University Institute of Sports Medicine, Prevention and Rehabilitation, coordinated by the Paracelsus Medical University in cooperation with the Ludwig Boltzmann Institute for Rehabilitation Research and the Ludwig Boltzmann Institute for Digital Health and Prevention within the Prehab2Rehab consortium. Approximately 30 adult patients, with the possibility to include up to 50 participants if feasible, will be consecutively recruited.\n\nThe intervention consists of a four-week multimodal prehabilitation program combining supervised exercise training, promotion of physical activity, nutritional counseling, psycho-oncological distress screening, and health literacy support. Digital tools will support the intervention throughout the perioperative pathway, including the HERO application (Das Herz Reha-Informationstool) for patient education and health literacy, aktivplan as a digital exercise planner and training diary, and the CAATS telecommunication platform for remote supervision and tele-prehabilitation sessions where appropriate.\n\nThe exercise intervention includes supervised center-based sessions and, for participants with longer travel distances, a hybrid model combining center-based and tele-prehabilitation sessions. Nutritional counseling will follow current European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines and includes screening for malnutrition risk. Psycho-oncological distress screening will follow recommendations of the German Cancer Society and includes referral to supportive care when clinically indicated.\n\nParticipants will be assessed throughout the perioperative pathway, including at the beginning and end of prehabilitation (Prehabilitation Assessment 1 \\[PRE1\\] and Prehabilitation Assessment 2 \\[PRE2\\]), during hospitalization and rehabilitation, and at a three-month follow-up after surgery. Primary outcomes focus on feasibility, including recruitment and retention rates, adherence, fidelity, safety, data management feasibility, and acceptability and usability of the digital technologies. Secondary outcomes include clinical recovery indicators, postoperative complications, length of hospital and intensive care stay, functional independence, psychological well-being, quality of life, body composition, cardiorespiratory fitness, functional exercise capacity, and muscle strength.\n\nTo contextualize outcomes, two historical comparator cohorts will be used: a local hospital cohort of patients who previously underwent similar surgery without prehabilitation, and a national rehabilitation cohort derived from routine rehabilitation datasets matched for diagnosis, sex, and age.\n\nThe study is intended to generate feasibility data and preliminary estimates that may support the development of future adequately powered randomized controlled trials evaluating digitally supported prehabilitation and rehabilitation pathways in visceral oncologic surgery.",[258,259,260,261,262,41,37,263,264],"Gastrointestinal Neoplasms","Pancreatic Neoplasms","Liver Neoplasm","Oesophageal Cancer","Gastrointestinal Cancer","Prehabilitation","Cancer Rehabilitation",[263,266,267,268,269,270,271,272,273,274],"Visceral Surgery","Oncology","Rehabilitation","Digital Health","Exercise Therapy","Teleprehabilitation","Cancer Surgery","Preoperative Care","Functional Recovery","2026-06-16",{"date":277,"type":49},"2026-06-18",{"date":216,"type":20},{"date":280,"type":20},"2027-07",{"name":282,"class":56},"Ludwig Boltzmann Institute for Digital Health and Prevention",2,{"id":285,"slug":4,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":290,"maxAge":147,"enrollmentInfo":291,"targetDuration":4,"studyType":21,"phases":293,"briefSummary":294,"conditions":295,"keywords":300,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":245},"100641453","NCT07653594","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE): A Single Arm Pilot Study","Inclusion Criteria:\n\n* Age 50 to 80\n* Able to speak and understand English\n* Scheduled to undergo a surgery meeting the following criteria: (1) traditional open surgery (not laparoscopic or robotic) via laparotomy (midline or subcostal incisions), (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces\n* Participant reports pain intensity of 4\u002F10 or above to study staff on day 1 post-surgery or any other day post-surgery through discharge\n\nExclusion Criteria:\n\n* Significant visual impairment that has not been corrected\n* Significant hearing impairment that has not been corrected\n* Significant cognitive impairment that would prevent participant from participating in the study","50 Years",{"count":292,"type":20},20,[23],"Participants may take part in this study if they are scheduled to undergo a surgery that meets the following: (1) traditional open surgery via laparotomy, (2) length of surgery \\>3 hours, and (3) curative-intent surgical resection of a cancer in the stomach, pancreas, bile ducts, liver, or peritoneal surfaces. The purpose of this study is (1) to evaluate the feasibility of collecting blood samples prior to surgery, post-surgery and pre- music-assisted relaxation and imagery (MARI) intervention, and immediately post-MARI intervention and (2) to identify gene expression changes associated with MARI and explore their relationship with immediate changes in pain intensity. Participants will be in this study for the duration of their hospital admission for surgery.",[296,297,298,152,37,299],"Surgery","Stomach Cancer","Pancreas Cancer","Peritoneal Cancer",[301,302],"Music therapy","Music-assisted relaxation and imagery",{"date":304,"type":49},"2026-06-17",{"date":306,"type":20},"2027-01",{"date":308,"type":20},"2027-12",{"name":310,"class":56},"Case Comprehensive Cancer Center",{"id":312,"slug":4,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":316,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":21,"phases":319,"briefSummary":321,"conditions":322,"keywords":327,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":245},"100604152","NCT07145801","Y-90 Treatment Response Using Transarterial Radioembolization","Contrast-Enhanced Ultrasound Evaluation of Radioembolization Treatment Response","TARE","Inclusion Criteria:\n\n* Scheduled for TARE therapy of a treatment naïve HCC visible on ultrasound.\n* Be at least 18 years of age.\n* Be medically stable.\n* If a female of child-bearing age, must have a negative pregnancy test.\n* Have signed Informed Consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable.\n* Patients with known sensitivities to the components of Lumason.\n* Patients with known sensitivities to the components of Sonazoid.",{"count":254,"type":20},[320],"PHASE2","This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE). HCC is the third leading cause of cancer mortality worldwide and the single fastest growing cause of cancer mortality in the United States. TARE is recommended for 15-25% of HCC patients. Treatment response is generally evaluated using contrast-enhanced CT or MRI 1-2 months and 4-6 months post-TARE. Although TARE is an effective therapy, assessment of treatment response using CT\u002FMRI is challenging because CT\u002FMRI frequently diagnoses tumor response as equivocal or non-progressing for up to 6 months post-TARE based on LI-RADS criteria. This delay in diagnosing tumor viability subsequently delays needed retreatment and can even serve as a barrier to transplantation. Our prior work in HCC locoregional therapy has shown CEUS provides improved sensitivity in detecting viable tumor following transarterial chemoembolization relative to traditional CT\u002FMRI. Therefore, the investigators propose to evaluate both qualitative and quantitative CEUS as a tool for evaluating HCC post-TARE at similar time points of clinically recommended cross-sectional imaging, while also investigating the role of Kupffer phase imaging.\n\nThe investigators plan to enroll a total of 30 patients scheduled for TARE of a treatment naïve HCC over an 18-month period, allowing for a minimum of 6 months follow up. Patients will undergo a CEUS examination within two weeks of their first two clinically indicated CT\u002FMRI exams (obtained at Jefferson 1-2 months and 4-6 months post TARE). In patients retreated prior to their 4-6 month MRI, CEUS may also be performed in the absence of the MRI at this time point but prior to retreatment. Patients will be recruited across six major hospitals within the Jefferson Health Enterprise. Those eligible for participation will be identified by project co-investigators and contacted by the study coordinator to discuss participation and to explain the study. The patient will be given time to consider the risks and benefits of the study and ask questions about participation. If agreeable, the patient will then arrange with the project coordinator to come to Jefferson's center city campus to sign consent and take part in the research study.",[323,324,37,325,326,260],"HCC","Hepatocellular Carcinoma","Hepatic Neoplasm","Primary Liver Cancer",[328,316,329,330,331,332,323,333,334,335,336,337,338,339,340,341,342,343,344,345,346,347,348,349,350],"transarterial radioembolization","CEUS","contrast-enhanced ultrasound","hepatocellular","carcinoma","hepatocellular carcinoma (HCC)","liver cancer","liver tumors","liver lesions","microbubbles","liver parenchyma","liver imaging","HCC locoregional therapy","Ultrasound","Kupffer","Yttrium-90","tumor viability","time intensity curves","parametric maps","microbubble destruction","bolus contrast injection","CEUS biomarker","Y90 TARE","2026-06-08",{"date":353,"type":49},"2026-06-10",{"date":355,"type":49},"2025-09-11",{"date":357,"type":20},"2027-06-30",{"name":359,"class":56},"Thomas Jefferson University",{"id":361,"slug":4,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":142,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":368,"conditions":369,"keywords":370,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":4,"leadSponsor":380,"locationsCount":245},"100091519","NCT00451022","Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies","Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents","* INCLUSION CRITERIA:\n* Subjects who received poxviral vectors (vaccinia and\u002For fowlpox) or other vaccines utilizing gene transfer or any other immunotherapeutic agent through GMB, UOB and LTIB affiliated trials at the National Cancer Institute, as well as subjects at extramural sites receiving these agents as part of a multi-site trial. Available stored specimens obtained from NCI participants in GMB, UOB, and LTIB affiliated protocols may be transferred to this protocol for storage and eventual future research use.\n* Subjects must be \\>= 18 years of age.\n\nEXCLUSION CRITERIA:\n\nParticipants unwilling to participate.\n\n(Please note, participants may participate in this protocol and, at the same time, participate in an active treatment or continuing care study.)",{"count":367,"type":20},750,"This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup. The study does not involve the use of any drug or biologic agent. Participants will undergo an annual health history. Because certain viruses enter into cells and create proteins from the viral genes, the type of vaccine treatment used is referred to gene therapy. The genes expressed by poxviral vectors do not become part of the genetic material left behind. Because gene therapy is a somewhat new technology, a prolonged monitoring of patients' health status is necessary, according to new specific reporting requirements for harmful events in patients who undergo such gene therapy studies. The risk of any long-term negative effects from the gene therapy that patients had received is quite small. Still, it is important that there be updates at least annually. This annual monitoring of health status will extend for 15 years, according to guidelines from the Food and Drug Administration, or for as long as patients are willing to participate.\n\nPatients who received poxviral vectors (vaccinia or fowlpox, or both) at the National Cancer Institute, through a trial affiliated with the Laboratory of Tumor Immunology and Biology, may be eligible for this study.\n\nParticipants will be involved in the following forms of data collection:\n\n* Annual medical history and physical examinations for the first 5 years following the last vaccine.\n* Annual telephone contact during the last 10 years.\n* Health status check, including primary cancer status, secondary malignancies, neurologic disorders, autoimmune disorders, and hematologic disorders.\n* Blood tests for the presence of HIV antibodies.\n* Reporting of medical problems, including information on unexpected hospitalizations and medications.\n\nIf a participant has died, the study will document the cause of death and autopsy information if available.",[42,37,29,31,38],[371,372,373,374],"Gene Therapy","Long Term Survivor","Research Specimen","Natural History","2026-06-04",{"date":377,"type":49},"2026-06-05",{"date":379,"type":49},"2004-09-13",{"name":381,"class":382},"National Cancer Institute (NCI)","NIH",{"id":384,"slug":4,"hasResults":11,"nctId":385,"briefTitle":386,"officialTitle":387,"acronym":4,"eligibilityCriteria":388,"healthyVolunteers":142,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":4,"leadSponsor":404,"locationsCount":245},"100060621","NCT00034216","Collection of Blood From Patients With Cancer","Biospecimen Acquisition From Human Subjects","* INCLUSION CRITERIA:\n\nPatients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible.\n\nPerformance status of ECOG 0, 1, 2, or 3 for admission to this protocol.\n\nAbility to understand and the willingness to sign a written informed consent document.\n\nINCLUSION FOR APHERESIS:\n\nNote: Effective with Amendment CC, participants will no longer be asked to undergo apheresis. This content is being retained for historical reference.\n\nHemoglobin greater than or equal to 10 mg\u002FdL and platelet count \\> 75,000\u002Fmm(3)\n\nWeight greater than 25 kg\n\nHIV negative\n\nProthrombin Time - within normal limits\n\nPartial Thromboplastin Time - within normal limits\n\nMedically indicated central line in place or adequate peripheral venous access\n\nEXCLUSION CRITERIA:\n\nNone.",{"count":390,"type":20},1750,"This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment.\n\nParticipants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.",[42,29,31,38,37],[394,395,396,374,109,397,398],"Suppressor Cells","T-cells","CD4+ \u002F CD25+ cells","Malignancy","Blood Sample","2026-05-29",{"date":401,"type":49},"2026-06-01",{"date":403,"type":49},"2002-07-16",{"name":381,"class":382},{"id":406,"slug":4,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":21,"phases":413,"briefSummary":415,"conditions":416,"keywords":421,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":429,"locationsCount":245},"100581542","NCT06851663","Trop2-targeted immunoPET Imaging of Solid Tumors","Inclusion Criteria:\n\n* Aged 18-75 year-old and of either sex\n* Histologically confirmed diagnosis of solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) or suspected solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) by diagnostic imaging;\n* Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n* Pregnancy；\n* Severe hepatic and renal insufficiency;\n* Allergic to single-domain antibody radiopharmaceuticals.","75 Years",{"count":412,"type":20},400,[320,414],"PHASE3","This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography\u002Fcomputed tomography (immunoPET\u002FCT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in solid tumors (including uroepithelial cancer, bladder cancer, prostate cancer, lung cancer, nasopharyngeal cancer, liver cancer, cholangiocarcinoma, ovarian cancer, cervical cancer, endometrial cancer, thyroid cancer, head and neck cancer) will be evaluated.",[417,418,419,72,42,38,165,37,420,40,30,32,83,39],"Solid Tumor","Solid Carcinoma","Uroepithelial Carcinoma","Cholangiocarcinoma",[422,423,417],"Trophoblast cell surface antigen 2 (Trop2)","ImmunoPET","2026-05-27",{"date":399,"type":49},{"date":427,"type":49},"2024-12-23",{"date":308,"type":20},{"name":430,"class":56},"RenJi Hospital",{"id":432,"slug":4,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":21,"phases":438,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":245},"100536304","NCT06263088","EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.","Inclusion Criteria:\n\n1. Adult ≥ 18 years old.\n2. Newly diagnosed Black GI cancer participants irrespective of stage. Eligible tumor types include anal carcinoma, rectal cancer, colon cancer, small bowel cancer, appendix carcinoma, hepatobiliary cancer, pancreatic cancer, gastroesophageal cancer, gastrointestinal neuroendocrine tumors, and gastrointestinal stromal tumor.\n3. Patient able and willing to comply with study procedures\n4. The patient is able to understand and willing to sign and date the written informed consent form at the screening visit.\n\nExclusion Criteria:\n\n* NONE",{"count":437,"type":20},200,[23],"This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder, liver, neuroendocrine tumor of gastrointestinal origin).\n\nThis study has 3 components as follows-\n\n1. Ensuring appropriate biomarker testing and evidence-based care: Biomarkers are molecules in the tumor or blood that indicate normal or abnormal processes in participant's body and may indicate an underlying condition or disease. Various molecules, such as DNA (genes), proteins, or hormones, can serve as biomarkers since they all indicate something about participant's health. Biomarker testing can also help choose participant's treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to participant's treating physician. Participants will receive standard-of-care treatment if participant enroll in this study. Participant will not receive any experimental treatment.\n2. Assistance with clinical trial enrollment. The study team will help participants enroll in a clinical trial appropriate for participant's condition. However, enrolling in a clinical trial is totally up to the participant.\n3. Health literacy: The study team will provide information relevant to participant's diagnosis to enrich participant's understanding of participant's condition and treatment. Investigator will provide questionnaires to assess participant's understanding before and after participant's have been provided with educational\u002Finformational material appropriate for participant's diagnosis.",[262,31,43,27,33,297,441,298,37,175],"Appendix Cancer",[443,444],"Gastrointestinal cancer","African Americans","2026-05-19",{"date":447,"type":49},"2026-05-22",{"date":449,"type":49},"2024-12-01",{"date":451,"type":20},"2026-09-30",{"name":310,"class":56},{"id":454,"slug":4,"hasResults":11,"nctId":455,"briefTitle":456,"officialTitle":456,"acronym":457,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":459,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":461,"conditions":462,"keywords":467,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":478},"100453457","NCT05184790","LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology","LEARN","Inclusion Criteria:\n\n* Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre.\n* Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy.\n* Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites.\n* Provides written informed consent.\n\nExclusion Criteria:\n\n* Less than 18 years of age",{"count":460,"type":20},300,"This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance.\n\nRoutinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.",[463,29,464,465,36,39,37,41,466],"Arrhythmias, Cardiac","Prostatic Cancer","Brain Cancer","Spinal Neoplasm",[468,469],"Radiation Therapy","markerless tracking","2026-05-18",{"date":445,"type":49},{"date":473,"type":49},"2023-02-28",{"date":475,"type":20},"2028-01-31",{"name":477,"class":56},"University of Sydney",4,{"id":480,"slug":4,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":147,"enrollmentInfo":485,"targetDuration":4,"studyType":21,"phases":487,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":495,"leadSponsor":497,"locationsCount":4},"100638399","NCT07587034","HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer","MATCH-001: A Multicenter, Open-Label, Randomized Controlled Trial of Hepatic Arterial Infusion Chemotherapy Followed by Transarterial Chemoembolization Combined With Apatinib and Camrelizumab in Patients With Intermediate and Advanced Hepatocellular Carcinoma","Inclusion Criteria\n\n1. Age 18-80 years.\n2. Diagnosed with hepatocellular carcinoma (HCC) in accordance with the Standardization for Diagnosis and Treatment of Primary Hepatic Carcinoma (2024 Edition) issued by the National Health Commission of the People's Republic of China.\n3. BCLC stage B or C, with no indication or refusal of surgical treatment, and measurable lesions meeting the mRECIST (Modified Response Evaluation Criteria in Solid Tumors) criteria on baseline imaging.\n4. Child-Pugh liver function grade A or well-compensated grade B (score ≤7).\n5. ECOG Performance Status (PS) score 0-1.\n6. Expected survival time ≥12 weeks.\n\nExclusion Criteria\n\n1. Prior transarterial chemoembolization (TACE) or other local therapies for HCC (except bridging liver transplantation).\n2. Active viral hepatitis (hepatitis B or C) with pre-treatment viral load \\>100 IU\u002FmL (positive for HCV RNA or HBV DNA) or without consistent antiviral therapy.\n3. Alcohol abuse or pregnancy.\n4. Concurrent other malignancies or history of other malignancies within the past 3 years.\n5. Renal dysfunction (creatinine \\[Cr\\] \\>2 mg\u002FdL or creatinine clearance \\[CCr\\] \\\u003C30 mL\u002Fmin) or severe organic diseases of vital organs (heart, lung, brain, etc.).\n6. Inability to cooperate with interventional procedures.\n7. Presence of distant metastasis.\n8. Main portal vein tumor thrombus accompanied by impaired portal venous blood flow and collateral circulation.\n\nWithdrawal Criteria\n\n1. Identification of non-compliance with the study protocol during the trial.\n2. Administration of radiotherapy or other interventions during the trial that prevent efficacy evaluation.\n3. Discontinuation of treatment due to severe adverse reactions (excluded from efficacy analysis but included in adverse reaction statistics).\n4. Patient or representative withdraws informed consent or requests to stop treatment.\n5. Loss to follow-up or death of the patient.\n\nKey Terminology Notes\n\n* National Health Commission of the People's Republic of China: Official English name of the Chinese health authority, consistent with government documentation.\n* Standardization for Diagnosis and Treatment of Primary Hepatic Carcinoma (2024 Edition) : Translated title of the 2024 national guideline for HCC diagnosis and treatment, aligning with the 2022 edition's official English translation published in Cancer Research on Prevention and Treatment.\n* mRECIST: Abbreviation for Modified Response Evaluation Criteria in Solid Tumors, the standard for assessing treatment response in HCC, widely used in clinical trials.\n* BCLC Staging: Barcelona Clinic Liver Cancer staging system, a globally recognized framework for HCC prognosis and treatment decision-making.\n* Child-Pugh Score: A widely used tool to assess liver function in patients with cirrhosis, with grades A (5-6 points), B (7-9 points), and C (10-15 points).\n* ECOG PS Score: Eastern Cooperative Oncology Group Performance Status, a scale from 0 (fully active) to 5 (dead) used to evaluate a patient's ability to perform daily activities.",{"count":486,"type":20},315,[488,320],"PHASE1","To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.",[37],"2026-05-16",{"date":493,"type":49},"2026-05-20",{"date":216,"type":20},{"date":496,"type":20},"2029-12",{"name":498,"class":56},"Shanghai Zhongshan Hospital",{"id":500,"slug":4,"hasResults":11,"nctId":501,"briefTitle":502,"officialTitle":502,"acronym":4,"eligibilityCriteria":503,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":147,"enrollmentInfo":504,"targetDuration":505,"studyType":68,"phases":4,"briefSummary":506,"conditions":507,"keywords":513,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":517,"leadSponsor":519,"locationsCount":522},"100637253","NCT07602504","China Metastatic Liver Cancer Clinical Registry Cohort Database","Inclusion Criteria:\n\n1. Patients with histologically or radiologically confirmed metastatic liver cancer.\n2. Age ≥ 18 years.\n3. Patients who have voluntarily signed the informed consent form.\n4. Patients with complete baseline clinical data.\n\nExclusion Criteria:\n\n1. Patients with primary liver cancer (e.g., hepatocellular carcinoma).\n2. Patients with other malignant tumors that may interfere with the evaluation of liver metastasis.\n3. Patients who have previously participated in other interventional clinical trials.\n4. Patients with severe cognitive disorders or communication barriers that prevent informed consent.\n5. Patients with incomplete or missing key clinical data.",{"count":106,"type":20},"10 Years","This study is led by the Department of Hepatobiliary Surgery of the First Affiliated Hospital of the University of Science and Technology of China (USTC), in close collaboration with multiple participating centers nationwide. The primary objective is to establish a standardized, large-scale clinical cohort database specifically for metastatic liver cancer. By collecting comprehensive data on patient demographics, primary tumor characteristics, systemic therapies, and local interventions, this registry aims to elucidate the clinical patterns and prognostic factors of secondary liver malignancies. This database will serve as a robust platform for conducting high-quality real-world studies and advancing evidence-based clinical research in the management of metastatic liver cancer.",[508,509,37,510,511,512],"Liver Metastases","Metastases to Liver","Neoplasms","Liver Diseases","Colorectal Cancer Metastatic",[514],"Liver Metastases; Metastatic Colorectal Cancer",{"date":447,"type":49},{"date":401,"type":20},{"date":518,"type":20},"2036-05-31",{"name":520,"class":521},"Anhui Provincial Hospital","OTHER_GOV",3,{"id":524,"slug":4,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":4,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":21,"phases":531,"briefSummary":532,"conditions":533,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":245},"100567833","NCT06673329","Brodalumab in the Treatment of Immune-Related Adverse Events","Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study","Inclusion Criteria:\n\n* Ability to provide written informed consent by subject or guardian\n* Individuals \\>18 years of age\n* Diagnosis of an irAE clinically suspected to be IL-17 mediated\n* Intent-to-treat or prior treatment with systemic steroids for irAE management\n* Histology-proven primary advanced or metastatic solid organ malignancy treated with immunotherapy. Patients being treated with curative intent are not eligible to enroll.\n* Subject has a negative test for tuberculosis during screening defined as either: negative purified protein derivative (PPD) (\\\u003C 5 mm of induration at 48 to 72 hours after test is placed) OR negative QuantiFERON test. Tuberculosis testing must be performed within 30 days prior to trial initiation.\n* Subjects with a positive PPD and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative QuantiFERON test.\n* Subjects with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or subjects with a positive or indeterminate QuantiFERON test are allowed if they have all of the following: no symptoms of tuberculosis (defined as fever, shortness of breath, cough or night sweats), documented history of a completed course of adequate prophylaxis (per local standard of care), no known exposure to a case of active tuberculosis after most recent prophylaxis, no evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of brodalumab.\n\nExclusion Criteria:\n\n* Estimated creatinine clearance \\\u003C 40 mg\u002Fmin\n* Active suicidal ideation or severe depression (as defined by the Diagnostic and Statistical Manual of Mental Disorders Version IV criteria (DSM-IV)) at the time of enrollment or a PHQ-9 score \\> 20\n* History of prior suicide attempts\n* PHQ-9 score greater \\>5 and \\\u003C 20 without an established mental health provider who verifies stability in their depression\n* Current or prior drug or alcohol abuse within the past 6 months (as defined by the DSM IV)\n* In the opinion of the investigator, the patient requires additional immunosuppressive treatment (other than corticosteroids and brodalumab)\n* Known hypersensitivity or contraindication to brodalumab, corticosteroids or any components of brodalumab\n* Prior treatment with brodalumab\n* Pregnancy, breastfeeding, or use of a nonreliable method of contraception\n\n  * For patients assigned female at birth: lack of willingness to use highly effective methods of birth control during treatment and for at least 4 weeks after the last dose of brodalumab (except if surgically sterile or at least 2 years postmenopausal, with postmenopausal status confirmed by Follicle-Stimulating Hormone (FSH) in the postmenopausal range).\n  * Highly effective methods of birth control include: use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Oral contraceptive pills must be supplemented by a barrier method.\n  * Patients planning to become pregnant while enrolled in the study and within 4 weeks after the last dose of brodalumab will not be permitted to enroll\n* Chronic or current severe infection requiring IV therapy\n* Evidence of active hepatitis B, C, or tuberculosis.\n* History of latent tuberculosis infection which is incompletely treated based upon local standard of care or which was never treated\n* History of or active Crohn's disease.\n* Myocardial infarction, unstable angina pectoris or stroke within the past 12 months prior to the first investigational product dose\n* Any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.\n* Any medical condition or treatment for a condition that, in the opinion of the investigator, might interfere with participation in the study or affect the reliability of clinician assessment or patient self-report\n* Other known clinically significant active medical conditions, such as:\n\n  * Severe cardiovascular disease, including advanced heart failure (American Heart Association Stage D)\n  * Aspartate aminotransferase (AST) and or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal or greater than 3 times the upper limit of normal in patients with liver metastases measured on at least two separate occasions\n  * Direct bilirubin greater than or equal to 1.5 mg\u002FdL in patients with or without liver metastases\n  * Bone marrow insufficiency unrelated to the irAE (according to investigator judgment) with White Blood Cell (WBC) \\\u003C2000\u002Fmm3, absolute neutrophil count \\\u003C1500\u002F mm3, thrombocytopenia (platelet count) \\\u003C50,000\u002Fmm3, hemoglobin \\\u003C 8.0 g\u002FdL\n* Plan to proceed with further curative intent treatment for cancer at the time of enrollment despite the presence of irAE\n* Participation in another therapeutic clinical trial and receipt of investigational drugs within 4 weeks before the screening visit\n* Previous diagnosis of an autoimmune disease or administration of immunosuppressants in a time frame that would impede interpretation of brodalumab administration\n* Planned use of immunosuppressive agents other than steroids (including infliximab, vedolizumab, tocilizumab etc.) or administration of such agents within 28 days of trial initiation\n* Administration of live-virus vaccines within 4 weeks before the first dose of brodalumab",{"count":530,"type":20},11,[488],"The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.",[29,33,36,38,83,534,41,297,535,31,43,39,536,37,117,42,81,417],"Gynecologic Cancer","Brain Tumor","Oral Cancer","2026-05-11",{"date":539,"type":49},"2026-05-13",{"date":541,"type":49},"2025-03-11",{"date":543,"type":20},"2027-11",{"name":545,"class":56},"Brian Henick, MD",{"id":547,"slug":4,"hasResults":11,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":21,"phases":554,"briefSummary":555,"conditions":556,"keywords":558,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":564,"leadSponsor":566,"locationsCount":245},"100581631","NCT06852820","68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)","A Pilot Study of 68Ga-PSMA-11 PET-directed Radioligand Therapy in Patients With Metastatic Hepatocellular Carcinoma (HCC)","Inclusion Criteria:\n\n* Participants must have histologically, cytologically or radiographically confirmed hepatocellular carcinoma by LI-RADS30 with metastatic and\u002For unresectable disease.\n* Participants must have received one prior line of systemic therapy for the treatment of metastatic and\u002For unresectable HCC including anti-PD-L1 therapy. Participants will be enrolled at the time of progression on first-line therapy for metastatic and\u002For unresectable disease.\n* Age \\>18 years. Because no dosing or adverse event data are currently available on the use of 177Lu-PSMA-617 (Lu-177 vipivotide tetraxetan) in participants \\\u003C18 years of age, children are excluded from this study.\n* ECOG performance status 0 or 1.\n* Participants must have normal organ and marrow function as defined below:\n\nAbsolute Neutrophil Count ≥ 1,500\u002FmcL. Hemoglobin \\> 9 g\u002FdL. Platelet count ≥ 75,000\u002FmcL. Serum creatinine ≤ 1.5 x institutional upper limit of normal or CrCl ≥60 mL\u002Fmin using the Cockroft-Gault formula for participants with creatinine levels \\>1.5 ULN.\n\nChild-Pugh class A or B7.\n\n* At least one target lesion measurable by RECIST 1.1 criteria.\n* PSMA-PET demonstrating PSMA PET positive lesion (higher uptake in the tumor compared with background liver uptake).\n* Participants must have the ability to understand and the willingness to sign a written informed consent document.\n* Participants of childbearing age are using an appropriate method of contraception.\n\nExclusion Criteria:\n\n* Participants receiving any other investigational agents.\n* Subject has received investigational therapy within 4 weeks or within 5 half-lives of the therapeutic agent (whichever is shorter).\n* Ongoing grade 3 or higher toxicity from prior anticancer systemic therapy.\n* Prior treatment with Y90 radioembolization for hepatocellular carcinoma.\n* Participants who have undergone major surgery within 3 months of screening and have not adequately recovered.\n* Known additional malignancy that currently requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.\n* Participants with untreated brain metastases and\u002For carcinomatous meningitis will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Participants with previously treated brain metastases may participate provided they are stable without evidence of new or enlarging brain metastases and are not using steroids for at least 7 days prior to trial treatment.\n* Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n* Participants with known psychiatric or substance use disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the treating investigator.\n* Subject is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 7 months for females and 14 weeks for males after the last dose of trial treatment. Pregnant or breastfeeding women are excluded from this study because 177Lu-PSMA-617 has not been previously studied in this population and the potential for teratogenic or abortifacient effects are unknown. Because there is an unknown but potential risk for adverse events in nursing infants secondary to the treatment of the mother with 177Lu-PSMA-617, breastfeeding should be discontinued if the mother is treated with 177Lu-PSMA-617. These potential risks may also apply to 68Ga-PSMA-11 used in this study.\n* Subject has received live vaccine within 30 days prior to the first dose of trial treatment.\n* Subject with recent variceal bleeding, gastrointestinal bleeding or high risk of bleeding.",{"count":553,"type":20},10,[320],"The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate specific membrane antigen (PSMA) positive liver cancer.",[37,324,557],"Metastatic Liver Cancer",[559],"Ga-PSMA-11","2026-05-06",{"date":562,"type":49},"2026-05-08",{"date":216,"type":20},{"date":565,"type":20},"2027-04-01",{"name":567,"class":56},"Melissa Lumish",{"id":569,"slug":4,"hasResults":11,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":142,"sex":16,"minAge":17,"maxAge":574,"enrollmentInfo":575,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":245},"100412937","NCT04657042","4D-MRI for Precision Medicine","Toward Precision Radiotherapy: Physiological Modeling of Respiratory Motion Based on Ultra-quality 4D-MRI","Inclusion Criteria:The inclusion criteria for lung and liver cancer patients are:\n\n* Patient is 21 or older\n* Patient has primary or metastatic tumor(s) in the lungs or the liver\n* Diameter of the tumor(s) is less than 7 cm\n* Patient will receive radiation therapy (ordered by the treating Radiation Oncologist) as part of their treatment regimen\n* Patient will undergo a planning CT scan with tumor motion assessment (planning 4D-CT ordered by the treating Radiation Oncologist) as part of their treatment regimen\n* Patient has signed informed consent and is willing to comply with the 4D-MRI imaging protocol\n\nThe inclusion criteria for healthy volunteers are:\n\n* Subject is 18 or older\n* Subject has signed informed consent and is willing to comply with the 4D-MRI imaging protocol\n\nExclusion Criteria:\n\n* Any condition for which a MRI procedure is contraindicated including presence of metallic material in the body, such as pacemakers, non- MRI compatible surgical clips, shrapnel, etc.\n* Subjects who have difficulty lying flat on their back for extended periods of time\n* Patients with any serious\u002Fpoorly controlled medical or psychological conditions that would complicate protocol compliance\n* Too large to adequately fit in the magnet bore or RF coils\n* Claustrophobia\n* Females who are pregnant or lactating\n* Presence of active or chronic infection","82 Years",{"count":67,"type":20},"The purpose of this study is to develop new ways to make medical images of the lungs and liver of adults using a technique called four-dimensional magnetic resonance imaging (4D-MRI). This technique produces three-dimensional movies of the inside of the chest and abdomen while the patient is breathing. (The fourth dimension is time!)\n\nThis new way of medical imaging is being developed to help cancer patients undergoing radiation therapy. Radiation therapy is used to treat cancerous tumors. For radiation therapy to be effective, the precise size, shape, and location of the tumor within the body must be known. A particular difficulty for radiation treatment of lung and liver cancer is that the tumor moves during treatment because the patient is breathing. Therefore, tumor motion must also be incorporated into the treatment plan. This study aims to improve radiation treatment planning through better targeting and dose estimation based on 4D-MRI. Before this new imaging method can be used for radiation treatment planning, it must be tested in living, breathing volunteers.",[578,37,38],"Healthy Volunteers","2026-04-30",{"date":560,"type":49},{"date":582,"type":49},"2020-11-05",{"date":584,"type":20},"2030-12-31",{"name":586,"class":56},"University of Virginia",{"id":588,"slug":4,"hasResults":11,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":11,"sex":16,"minAge":143,"maxAge":4,"enrollmentInfo":593,"targetDuration":4,"studyType":21,"phases":595,"briefSummary":596,"conditions":597,"keywords":598,"overallStatus":211,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":245},"100610321","NCT07226063","Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer","A Phase II Study of Maintenance Zanzalintinib and Durvalumab in Patients With Advanced Hepatocellular Cancer After Induction Tremelimumab Plus Durvalumab","Inclusion Criteria:\n\n* Participants must have radiographically or histologically or cytologically confirmed hepatocellular cancer. Participants must have advanced cancer (metastatic or unresectable) requiring systemic therapy.\n* Participants must be treated with tremelimumab plus durvalumab and have stable disease or response to therapy. Participants must have received 2 to 5 doses of durvalumab prior to starting treatment on the clinical trial.\n* Age \\>18 years. Because no dosing or adverse event data are currently available on the use of durvalumab in combination with zanzalintinib in participants ≤18 years of age, children are excluded from this study.\n* ECOG Performance status 0-2.\n* Participants must have normal organ and marrow function as defined below based upon meeting all the following laboratory criteria within 14 days before first dose of study treatment:\n\n  * Absolute neutrophil count ≥ 1,500\u002FmcL 1,500\u002FmcL (without granulocyte colony-stimulating factor support within 2 weeks of screening laboratory sample collection)\n  * Hemoglobin ≥ 9 g\u002FdL (≥ 90 g\u002FL) without transfusion within 2 weeks prior to screening laboratory sample collection.\n  * Platelet count ≥ 75,000\u002FmcL\n  * Total bilirubin \\\u003C 2.0 mg\u002FdL or \\\u003C2x upper limit of normal (ULN) whichever is higher\n  * AST (SGOT) ≤ 5 X institutional upper limit of normal\n  * ALT (SGPT) ≤ 5 X institutional upper limit of normal\n  * Creatinine clearance ≥ 40 mL\u002Fmin (≥ 0.67 mL\u002Fsec) using the Cockcroft Gault equation\n  * International Normalized Ratio (INR) ≤ 1.7 and\u002For activated partial thromboplastin time (aPTT) ≤ 1.2 x ULN.\n  * Serum albumin at least 2.5g\u002FdL for Child-Pugh A\n  * Urine protein-to-creatinine ratio (UPCR) ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol) creatinine\n* Child Pugh Score A 5-6\n* Participants must have the ability to understand and the willingness to sign a written informed consent document.\n* At least one index lesion that is measurable based on RECIST 1.1.\n* Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from AEs, including immune-related adverse events (irAEs), related to any prior treatments, unless AE(s) are clinically nonsignificant and\u002For stable on supportive therapy (eg, physiological replacement of corticosteroid). Low-grade or controlled toxicities such as alopecia, ≤ Grade 2 fatigue, ≤ Grade 2 hypomagnesemia, ≤ Grade 2 neuropathy are permitted)\n* Sexually active fertile participants and their partners must agree to use highly effective method of contraception during the course of the study and for the following durations after the last dose of zanzalintinib or duvalumab whichever was administered later. An additional contraceptive method, such as a barrier method (eg, condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.\n\n  * through 186 days after the last dose of zanzalintinib or durvalumab for women of childbearing potential (WOCBP) or through 96 days after the last dose of zanzalintinib or durvalumab for men\n* Female participants of childbearing potential must not be pregnant at screening. Female participants are considered to be of childbearing potential unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \\\u003C 55 years-of-age must have a serum follicle stimulating hormone \\[FSH\\] level \\> 40 mIU\u002FmL to confirm menopause). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.\n\nExclusion Criteria:\n\n* Inability to swallow tablets or ingest a suspension either orally or by a nasogastric (NG) or gastrostomy (PEG) tube.\n* Participants receiving any other investigational agents concurrently for cancer treatment.\n* Participants with untreated brain metastases\u002FCNS disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.\n* History of solid organ or allogeneic stem cell transplant.\n* Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements. This includes unstable or deteriorating cardiovascular disorders:\n\n  * Congestive heart failure New York Heart Association Class 3 or 4, class 2 or higher, unstable angina pectoris, new-onset angina, serious cardiac arrhythmias (eg, ventricular flutter, ventricular fibrillation, Torsades de pointes).\n  * Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 140 mm Hg systolic or \\> 90 mm Hg diastolic despite optimal antihypertensive treatment.\n  * Stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction, or other clinically significant arterial thrombotic and\u002For ischemic event within 6 months before first dose of study treatment.\n  * Pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous events within 3 months before first dose of study treatment.\n  * Note: Participants with a diagnosis of DVT within 6 months are allowed if asymptomatic and stable at screening and are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen. Note: Participants who don't require prior anticoagulation therapy may be eligible but must be discussed and approved by the Principal Investigator.\n  * Prior history of myocarditis.\n  * Gastrointestinal (GI) disorders associated with a high risk of perforation or fistula formation:\n  * Tumors invading the GI-tract from external viscera\n  * Active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis\n  * Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months before first dose unless cause of obstruction is definitively managed and participant is asymptomatic\n  * Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose. Note: Complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n  * Known gastric or esophageal varices\n  * Ascites, pleural effusion, or pericardial fluid requiring drainage in last 4 weeks\n* Active infection requiring systemic treatment. Note: Prophylactic antimicrobial treatments (antibiotics, antimycotic, antiviral) are allowed.\n\n  * Known infection with acute or chronic hepatitis B or C, known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness except for participants meeting all of the following criteria: (1) on stable anti-retroviral therapy; (2) CD4+ T cell count ≥ 200\u002FµL; and (3) an undetectable viral load. Note: HIV testing will be performed at screening if and as required by local regulation. Note: To be eligible, participants taking CYP inhibitors (eg, zidovudine, ritonavir, cobicistat, didanosine) or CYP3 inducers (efavirenz) must change to a different regimen not including these drugs 7 days prior to initiation of study treatment. Anti-retroviral therapies (ART) must have been received for at least 4 weeks prior to the first dose. Note: CD4+ T cell counts, and viral load are monitored per standard of care by the local health care provider. Following illnesses\u002Fconditions are also excluded\n  * Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.\n  * Malabsorption syndrome.\n  * Pharmacologically uncompensated, symptomatic hypothyroidism.\n  * Requirement for hemodialysis or peritoneal dialysis\n* Prior treatment with tyrosine kinase inhibitors for HCC\n* Another malignancy that requires active therapy and in the opinion of the Investigator would interfere with monitoring of radiologic assessments of response to Investigational Product, within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy. Incidentally diagnosed prostate cancer is allowed if assessed as stage ≤ T2N0M0 and Gleason score ≤ 6.\n* Active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids (prednisone \\>10 mg daily orally) or immunosuppressive agents. Participants with durvalumab related adverse event can be included in the trial as long as participants are not requiring prednisone (or equivalent) \\> 20 mg daily dosing.\n* Pregnant or breastfeeding women are excluded from this study because durvalumab and zanzalintinib has the potential for teratogenic effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued if the mother is treated on clinical trial. These potential risks may also apply to other agents used in this study.\n* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Participants with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n* Concomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin inhibitors ) and platelet inhibitors (eg, clopidogrel). Note: Participants must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first dose of study treatment, whichever is longer. Allowed anticoagulants are the following:\n\n  * Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n  * Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in participants without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen.\n* Any complementary medications (eg, herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.\n* Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 ml) of red blood, or other history of significant bleeding (eg, pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n* Lesions invading major blood vessel including, but not limited to, inferior vena cava, pulmonary artery, or aorta. Note: Participants with intravascular tumor extension (eg, tumor thrombus in renal vein or inferior V. cava) may be eligible following Principal Investigator approval. Participants with involvement of portal vein or hepatic vessels are allowed to participate.\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 480 ms within 14 days per electrocardiogram (ECG) before first dose of study treatment.\n\n  * Note: Triplicate ECG evaluations will be performed and the average of these 3 consecutive results for QTcF will be used to determine eligibility.\n* History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent.\n* Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n* Any active, known, or suspected autoimmune disease. Note: Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n* Known positive test for tuberculosis infection if supported by clinical or radiographic evidence of disease.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computerized tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Free thyroxine (FT4) outside the laboratory normal reference range. Asymptomatic participants with FT4 abnormalities can be eligible after Principal Investigator approval.\n* Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.\n* Documented hepatic encephalopathy (HE) within 6 months before first dose of study treatment.\n* Clinically meaningful ascites (ie, ascites requiring repeated paracentesis) within 6 months before first dose of study treatment.\n* Participants who have received any local anticancer therapy including surgery, PEI, RFA, MWA, trans arterial chemoembolization (TACE), or trans arterial radioembolization (TARE) within 28 days prior to first dose of study treatment. Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 8 weeks prior to first dose of study treatment. Prior laparoscopic surgeries (ie nephrectomy) within 4 weeks prior to first dose of study treatment. Minor surgery (eg, simple excision, tooth extraction) within 5 days before first dose of study treatment. Complete wound healing from major or minor surgery must have occurred at least prior to first dose of study treatment.",{"count":594,"type":20},16,[320],"This research study is for people who were treated with tremelimumab and durvalumab for advanced liver cancer and who are currently receiving durvalumab. Participants in this study will receive a drug called zanzalintinib. They will also continue receiving durvalumab. Studies have shown that patients with advanced liver cancer who had tremelimumab and durvalumab may benefit from taking zanzalintinib while they are taking durvalumab. Zanzalintinib is an investigational drug. This means it has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced liver cancer. Durvalumab is approved by the FDA for patients with advanced liver cancer. The purpose of this study is to find out if taking zanzalintinib with durvalumab will improve how long people with advanced liver cancer will live.",[324,37],[599,600],"Zanzalintinib","Durvalumab","2026-04-29",{"date":603,"type":49},"2026-05-05",{"date":605,"type":20},"2026-05",{"date":607,"type":20},"2028-08",{"name":609,"class":56},"Amit Mahipal",{"id":611,"slug":4,"hasResults":11,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":616,"enrollmentInfo":617,"targetDuration":4,"studyType":21,"phases":619,"briefSummary":620,"conditions":621,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":622,"lastUpdatePostDateStruct":623,"startDateStruct":625,"completionDateStruct":627,"leadSponsor":629,"locationsCount":283},"100597021","NCT07053072","PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.","A Prospective，Single Arm Clinicial Trial Evaluating PD-1 mRNA LNP Vaccine for the Treatment of Advanced Primary Hepatocellular Carcinoma Failing Standard Therapy","Inclusion Criteria:\n\n1. Male or female patients: ≥18 years of age; ≤70 years of age;\n2. Recurrent or metastatic hepatocellular carcinoma that has failed second-line standard therapy.\n3. Patients with at least one target lesion with a measurable diameter according to the RECIST criteria (CT scan of tumor lesions with a long diameter of ≥10mm, CT scan of lymph node lesions with a short diameter of ≥10mm and a layer thickness of no more than 5mm);\n4. ECOG physical condition score: 0 to 1;\n5. Expected survival ≥ 3 months;\n6. Good function of major organs, i.e., relevant examination indexes within 14 days prior to randomization meet the following requirements:\n\n   * Routine blood tests: hemoglobin ≥80g\u002FL (no blood transfusion within 14 days); neutrophil count \\>1.5×109 \u002FL; platelet count ≥80×109 \u002FL;\n   * Biochemical tests: total bilirubin ≤1.5 × ULN (upper limit of normal); blood alanine aminotransferase (ALT) or blood alanine transaminase (AST) ≤ 2.5 × ULN; if liver metastases, ALT or AST ≤ 5 × ULN; endogenous creatinine clearance ≥ 60 ml\u002Fmin (Cockcroft-Gault formula);\n   * cardiac Doppler ultrasound: left ventricular ejection fraction (LVEF) (LVEF) ≥50%.\n7. Good compliance and family agreement to cooperate in receiving survival follow-up.\n\nExclusion Criteria:\n\n1. Participation in a clinical trial of another drug within 4 weeks;\n2. Patients with a prior history of other neoplasms, unless cervical cancer in situ, treated squamous skin cancer or epithelial tumor of the bladder or other malignancies that have undergone radical therapy (at least 5 years prior to enrollment);\n3. Patients with uncontrolled cardiac clinical symptoms or disease, such as NYHA class 2 or higher heart failure, unstable angina pectoris , myocardial infarction within 1 year, clinically significant Supraventricular or ventricular arrhythmias requiring treatment or intervention.\n4. For female subjects: women who are pregnant or breastfeeding.\n5. Patients with active tuberculosis, bacterial or fungal infection (≥ grade 2 of NCI-CTCAE 5.0); HIV infection; active HBV infection; HCV infection.\n6. Those with a history of psychotropic substance abuse that they are unable to abstain from or those with mental disorders;\n7. Subjects with any active autoimmune disease or history of autoimmune disease (e.g., the following, but not limited to : uveitis, enteritis, pituitary gland inflammation, nephritis, hyperthyroidism, hypothyroidism; subjects with vitiligo or asthma that has resolved completely in childhood and does not require any intervention in adulthood may be enrolled; subjects with asthma requiring medical intervention with bronchodilators may not be enrolled).\n8. Patients who have been inoculated with mRNA drugs.\n9. Participation in clinical trials involving lipid nanoparticles, a component of the study vaccine.\n10. Contraindications to intramuscular injection.\n11. History of substance abuse or known medical, psychological or social conditions such as alcohol or drug abuse.\n12. Known allergy, hypersensitivity or intolerance to the investigational vaccine (including any excipients). Previous history of severe allergy to any drug, food, or vaccination, such as anaphylaxis, allergic laryngeal edema, allergic dyspnea, anaphylactic purpura, thrombocytopenic purpura, localized anaphylactic necrotic reaction (Arthus reaction).\n13. The female subject is planning to become pregnant or the male subject's partner is planning to become pregnant during the Screening Period and up to 12 months after the full course of drug administration.\n14. In the judgment of the investigator, there is a serious concomitant disease that jeopardizes the patient's safety or interferes with the patient's ability to complete the study.","70 Years",{"count":618,"type":20},9,[488],"Evaluating the Safety and Efficacy of PD-1 mRNA LNP Vaccine Therapy in Patients with Primary Hepatocellular Carcinoma Who Have Failed Advanced Standard Therapy",[37],"2026-04-19",{"date":624,"type":49},"2026-04-23",{"date":626,"type":49},"2025-10-23",{"date":628,"type":20},"2026-12-30",{"name":630,"class":56},"West China Hospital",{"id":632,"slug":4,"hasResults":11,"nctId":633,"briefTitle":634,"officialTitle":635,"acronym":4,"eligibilityCriteria":636,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":637,"enrollmentInfo":638,"targetDuration":4,"studyType":21,"phases":640,"briefSummary":641,"conditions":642,"keywords":653,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":661,"lastUpdatePostDateStruct":662,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":245},"100573965","NCT06753136","Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and\u002For Secondary Visceral Localizations, of Any Histotype","Treatment of Visceral Localizations With Electrochemotherapy in Patients With Primary Visceral Tumors and\u002For Secondary Visceral Localizations, of Any Histotype: Monocenter, Single Arm, Clinical Investigation","Inclusion Criteria:\n\n* Male\u002FFemale ≥ 18 years\n* Ability to understand the proposed treatment and express an informed acceptance by signing the informed consent\n* Diagnosis of primary and\u002For secondary visceral localizations of any histotype\n* Patients who are not eligible for standard curative procedures\n\nExclusion Criteria:\n\n* Absolute contraindications to invasive procedures\n* Concomitant presence of brain, lung, bone metastases\n* Uncorrectable coagulation changes\n* Bleomycin allergy\n* Absolute contraindications to taking Bleomycin\n* Poor respiratory function or pulmonary fibrosis\n* Acute lung infections\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study","99 Years",{"count":639,"type":20},24,[23],"This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneous metastases of different tumor histotypes.\n\nAlthough still limited, the various experiences in the treatment of visceral localizations, particularly in liver metastases from colorectal cancer are promising and show that electrochemotherapy is a safe treatment, even in the case of lesions near large vessels or nerves. The investigators therefore propose a clinical investigation with a Medical Device according to EU Regulation 745\u002F2017, using electrochemotherapy (Cliniporator) with bleomycin for the treatment of visceral, primary or secondary, unresectable localizations, with percutaneous or intraoperative technique (laparoscopic or laparotomy), as needed.",[643,644,37,645,74,646,647,648,649,650,651,652],"Primary Visceral Tumors of Any Histotype","Visceral Lesions","Liver Metastasis Colon Cancer","Primary Pancreatic Tumor","Retroperitoneal Sarcoma","Abdominal and\u002For Peritoneal Localizations","Merkel Cell Carcinoma","Squamous Cell Carcinoma","Secondary Visceral Localizations of Any Histotype","Non-melanoma Skin Cancer",[654,655,656,657,658,659,660],"electrochemotherapy","visceral lesions","Laparoscopic procedure","Laparotomic procedure","Percutaneous procedure","bleomycin","medical device","2026-04-09",{"date":663,"type":49},"2026-04-13",{"date":665,"type":49},"2025-07-23",{"date":667,"type":20},"2030-02-28",{"name":669,"class":56},"Istituto Oncologico Veneto IRCCS",{"id":671,"slug":4,"hasResults":11,"nctId":672,"briefTitle":673,"officialTitle":674,"acronym":4,"eligibilityCriteria":675,"healthyVolunteers":11,"sex":16,"minAge":676,"maxAge":677,"enrollmentInfo":678,"targetDuration":4,"studyType":21,"phases":679,"briefSummary":680,"conditions":681,"keywords":687,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":691,"lastUpdatePostDateStruct":692,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":245},"100417400","NCT04715191","Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as an Immunotherapy for Children With Solid Tumors (CARE)","Procurement Eligibility\n\nInclusion Criteria:\n\n* Diagnosis of GPC3-positive\\* solid tumors (as determined by immunohistochemistry with an extent score of \\>=Grade 2 \\[\\>25% positive tumor cells\\] and an intensity score of \\>= 2 \\[scale 0-4\\]).\n* Age ≥1 year and ≤ 21 years\n* Lansky or Karnofsky score ≥60%\n* Life expectancy ≥16 weeks\n* Barcelona Clinic Liver Cancer Stage A, B or C (for patients with hepatocellular carcinoma only)\n* Child-Pugh-Turcotte score \\\u003C7 (for patients with hepatocellular carcinoma only)\n* Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent\n\nExclusion Criteria:\n\n* History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies).\n* History of organ transplantation\n* Known HIV positivity\n* Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections)\n\nTreatment Eligibility\n\nInclusion Criteria:\n\n* Age ≥ 1 year and ≤ 21 years\n* Barcelona Clinic Liver Cancer Stage A, B or C (for patients with hepatocellular carcinoma only)\n* Lansky or Karnofsky score ≥ 60%\n* Child-Pugh-Turcotte score \\\u003C 7 (for patients with hepatocellular carcinoma only)\n* Adequate organ function:\n* Creatinine clearance as estimated by Cockcroft Gault or Schwartz ≥ 60 ml\u002Fmin\n* Total bilirubin \\\u003C 3 times ULN for age\n* INR ≤1.7 (for patients with hepatocellular carcinoma only)\n* Absolute neutrophil count \\> 750\u002Fµl\n* Platelet count \\> 75,000\u002Fµl (Needs to be confirmed prior to treatment whether with or without transfusion)\n* Hgb ≥ 8.0 g\u002Fdl (Needs to be confirmed prior to treatment whether with or without transfusion)\n* Pulse oximetry ≥ 92% on room air\n* Incurable disease after treatment with up- front therapy (Patients who have relapsed disease despite a standard of care salvage therapy)\n* Wash out period, such that patient has recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study, and returned to their clinical baseline, as determined by history and physical exam.\n* Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the T-cell infusion.\n* Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent\n\nExclusion Criteria:\n\n* Pregnancy or lactation\n* Uncontrolled infection\n* Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent\u002Fkg\u002Fday, dose adjustment or discontinuation of medication must occur at least 24 hours prior to CAR T cell infusion)\n* Known HIV positivity\n* Active bacterial, fungal or viral infection \\[except Hepatitis B (HBV patients with active disease who meet the criteria for anti-HBV therapy should be on a suppressive antiviral therapy prior to initiation of cancer therapy) or Hepatitis C virus infections (should have completed curative antiviral treatment with HCV viral load below the limit of quantification\\]\n* Congestive heart failure (as defined by New York Heart Association Functional Classification III or IV), unstable angina, serious uncontrolled cardiac arrhythmia, a myocardial infarction within 6 months prior to study entry or a history of myocarditis\n* Active autoimmune or inflammatory disorder\n* Live vaccines within 30 days prior to enrollment\n* History of organ transplantation\n* History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies)","1 Year","21 Years",{"count":639,"type":20},[488],"Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment.\n\nThe body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise, but have not been strong enough to cure most patients.\n\nInvestigators have found from previous research that they can put a new gene (a tiny part of what makes-up DNA and carries a person's traits) into T cells that will make them recognize cancer cells and kill them. In the lab, investigators made several genes called a chimeric antigen receptor (CAR), from an antibody called GPC3. The antibody GPC3 recognizes a protein found solid tumors including pediatric liver cancers. This CAR is called GPC3-CAR. To make this CAR more effective, investigators also added two genes that includes IL15 and IL21, which are protein that helps CAR T cells grow better and stay in the blood longer so that they may kill tumors better. The mixture of GPC3-CAR and IL15 plus IL21 killed tumor cells better in the laboratory when compared with CAR T cells that did not have IL15 plus IL21 .This study will test T cells that investigators made (called genetic engineering) with GPC3-CAR and the IL15 plus IL21 (CARE T cells) in patients with GPC3-positive solid tumors.\n\nT cells made to carry a gene called iCasp9 can be killed when they encounter a specific drug called AP1903. The investigators will insert the iCasp9 and IL15 plus IL21 together into the T cells using a virus that has been made for this study. The drug (AP1903) is an experimental drug that has been tested in humans with no bad side-effects. The investigators will use this drug to kill the T cells if necessary due to side effects.\n\nThis study will test T cells genetically engineered with a GPC3-CAR and IL15 plus IL21 (CARE T cells) in patients with GPC3-positive solid tumors.\n\nThe CARE T cells are an investigational product not approved by the Food and Drug Administration.\n\nThe purpose of this study is to find the biggest dose of CARE T cells that is safe, to see how long they last in the body, to learn what the side effects are and to see if the CARE T cells will help people with GPC3-positive solid tumors.",[37,682,683,684,685,686],"Rhabdomyosarcoma","Malignant Rhabdoid Tumor","Liposarcoma","Wilms Tumor","Yolk Sac Tumor",[688,689,690],"15.21.GPC3-CAR T cells","GPC3","Glypican","2026-04-01",{"date":693,"type":49},"2026-04-06",{"date":695,"type":49},"2024-05-24",{"date":697,"type":20},"2041-07-03",{"name":699,"class":56},"Baylor College of Medicine",{"id":701,"slug":4,"hasResults":11,"nctId":702,"briefTitle":703,"officialTitle":704,"acronym":4,"eligibilityCriteria":705,"healthyVolunteers":142,"sex":16,"minAge":706,"maxAge":707,"enrollmentInfo":708,"targetDuration":4,"studyType":21,"phases":709,"briefSummary":710,"conditions":711,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":712,"lastUpdatePostDateStruct":713,"startDateStruct":715,"completionDateStruct":717,"leadSponsor":719,"locationsCount":283},"100631721","NCT07504367","Large Language Models Assist in Tumor MDT","Evaluating Large Language Models as Decision Support Agents in Pan-Cancer Tumor Boards: A Randomized Controlled Trial","Inclusion Criteria:\n\n* A junior doctor with a practicing physician qualification certificate.\n* Oncologists, surgeons, radiation oncologists, radiologists and pathologists with 3 to 5 years of clinical experience.\n* Age: 25 to 33 years old, gender not limited.\n* During the research period, one can participate for no less than 10 hours.\n* Agree to participate in this research and sign the informed consent form.\n\nExclusion Criteria:\n\n* Have participated in the previous diagnosis and treatment of any one of the 20 cases included in the study.","25 Years","33 Years",{"count":228,"type":20},[23],"Multidisciplinary teams (MDTs) represent the gold standard for personalized tumor treatment, but they are limited by medical resources and accessibility Limitation. Although large language models (LLMs) have shown promise in medical reasoning, their multidisciplinary practicality in pan-cancer MDTs has not been fully explored. In the early stage of this project, LLMs with high clinical application efficacy were identified through benchmark tests, and an open-label randomized controlled study (RCT) was conducted based on these LLMs. The research aims to explore whether AI-assisted assistance can enhance the accuracy and writing efficiency of MDT diagnosis and treatment reports. This study intends to prospectively collect the diagnosis and treatment information of 20 patients and MDT diagnosis and treatment information. It is planned to recruit 40 junior doctors. Doctors in the intervention group will use LLM to assist in the writing of MDT reports, while doctors in the control group will use traditional information retrieval methods for the writing of MDT reports. Three clinical experts ultimately used a standardized Likert scale to conduct comprehensive and multidisciplinary scoring of the MDT reports of the intervention group and the control group. This study quantitatively compared the diagnosis and treatment quality and efficiency of the MDT AI-assisted model and the traditional model to verify the application potential of large language models in assisting tumor diagnosis and treatment.",[38,29,113,297,37],"2026-03-25",{"date":714,"type":49},"2026-03-31",{"date":716,"type":49},"2026-01-01",{"date":718,"type":20},"2026-12-31",{"name":720,"class":56},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":722,"slug":4,"hasResults":11,"nctId":723,"briefTitle":724,"officialTitle":725,"acronym":726,"eligibilityCriteria":727,"healthyVolunteers":142,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":728,"targetDuration":4,"studyType":68,"phases":4,"briefSummary":730,"conditions":731,"keywords":733,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":737,"lastUpdatePostDateStruct":738,"startDateStruct":739,"completionDateStruct":741,"leadSponsor":743,"locationsCount":245},"100550437","NCT06447064","Cancer Loyalty Card Study 2 (CLOCS-2)","Cancer Loyalty Card Study 2: a Retrospective Observational Case-Control Study","(CLOCS-2)","Inclusion Criteria (ALL):\n\n* Individuals aged \\>18 years of age\n* Individuals must be residing in the United Kingdom at the time of giving informed consent\n* Individuals must be registered with an NHS GP Practice\n* Individuals must meet the criteria of ONE of the groups. For example, to be eligible for Group 1 (Cases), individuals must have been diagnosed with one of the following cancer types in the last 24 months: Bladder, colorectal (bowel), endometrial, liver, oesophageal, ovarian, pancreatic, stomach (gastric), uterine, or vulval; whereas for Group 2 (Controls), individuals must not have received a cancer diagnosis of any type in the last 6 years (except where the diagnosis was of non-melanoma skin cancer).\n* Individuals must be a primary registered cardholder\\* of one of the loyalty cards listed below, and consent to share their loyalty card data with the study team\n* Tesco Clubcard\n* Boots Advantage Card\n* Provision of written informed consent\n* Willing and able to comply with all required study activities\n\n  * The primary registered card holder, i.e., the person who is named on the loyalty card account, must also enrol into the study, if someone other than the registered primary card holder from the same household, wants to take part in the study.\n\nExclusion Criteria (ALL):\n\n* Individuals under the age of 18 years\n* Non-UK residents, at the time of giving informed consent\n* Individuals without an eligible loyalty card, or who have no one in their household who has an eligible loyalty card\n* Individuals who are not the primary registered cardholder in their household and where the primary registered loyalty card holder is not willing to join the study, and\u002For where the primary registered cardholder does not make purchases for or on behalf of the individual\n\nExclusion Criteria (CASES):\n\n• Individuals will not be able to join as a case if:\n\n* they have been diagnosed with an eligible cancer type more than 24 months ago (except where the diagnosis was non-melanoma skin cancer).\n* they have received an ineligible cancer diagnosis within the last 6 years except where the diagnosis was non-melanoma skin cancer).\n\nExclusion Criteria (Controls):\n\n• Individuals will not be able to join as a control (Group 2) if:\n\no they have received any cancer diagnosis in the last six years (except where the diagnosis was non-melanoma skin cancer).",{"count":729,"type":20},2900,"Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spectrum, from the first observation of symptoms to the start of treatment. Diagnosing cancer when it is still at an early stage, before it has spread, gives surgery, radiotherapy and other treatments the best chance of working.\n\nTherefore, early diagnosis is the most important way to improve cancer outcomes.Most of the cancers usually presents with vague and non-alarming symptoms. Most individuals are diagnosed late when the cancer has already spread, and the prognosis is poor. There are over 200 different types of cancer that can cause many different signs and symptoms. Sometimes symptoms affect specific body areas, such as abdomen or skin. But signs can also be more general, and include weight loss, tiredness (fatigue) or unexplained pain. The type of symptoms varies from person to person.\n\nThe major reasons for not presenting to the GP with symptoms such as these are \"not wanting to waste the GP's time\" and normalisation of these symptoms.\n\nThe persistence of a symptom, social influence and awareness encourage help-seeking behaviours in primary care. However, few believe their symptom(s) might be a sign of cancer. Consequently, people might choose to self-manage their symptoms by using over-the-counter medication, and to seek advice from other sources, (pharmacists, family, internet), rather than a primary care physician.\n\nRATIONALE FOR CURRENT STUDY\n\nAn early cancer diagnosis is essential for receiving treatment as early as possible to have the best chance for successful treatment. Early diagnosis of cancer can be challenging. Sometimes, the cancer symptoms resemble common illnesses and could resolve with the use of over-the-counter medications and other remedies until they become persistent or debilitating. The present study focuses on ten cancer forms: colon, oesophageal, stomach, liver, bladder, uterine, vulval, ovarian, endometrial and pancreatic. Patients diagnosed with the cancers mentioned above often report experiencing vague symptoms (such as abdominal or back pain, indigestion, feeling full etc). They often use over-the-counter medication to manage their symptoms before seeing a doctor.\n\nInformation about how often and what products participants purchase (e.g. pain killers, digestive products and natural remedies) to care for these symptoms could help identify these cancers a few crucial weeks or months earlier and encourage people to seek help sooner from their doctors.",[41,31,261,297,37,72,732,86,40,32],"Uterine Cancer",[40,734,735,736],"Epidemiology","Observational Study","Risk Assessment","2026-03-24",{"date":712,"type":49},{"date":740,"type":49},"2026-02-04",{"date":742,"type":20},"2027-04",{"name":744,"class":56},"Imperial College London",""]